Template Provided By:

Cancer Imaging Program

National Cancer Institute

Not Responsible for Investigator's Use; Modifications are Prohibited.

Reagent/Supply Specification Sheet

(Refer to GEN-M001)

Reagent/Supply: **3'-Deoxy-3'-[^{19}F]Fluorothymidine** **Storage Conditions:** **2 - 8°C** *(if applicable)*

Internal Tracking Code: SS-FLT **MSDS On File? Y N N/A** *(circle one)*

Suppliers:

Vendor	Address	Telephone Number	MSDS Available	Vendor Designation (If Needed)
Sigma-Aldrich	**P.O. Box 2060 Milwaukee, WI 53201**	1-800-558-9160 (Fax) 1-800-962-9591	**Yes**	A
ABX	**ABX GmbH Heinrich-Glaeser-Strasse 10-14 D-01454 Radeberg Germany**	49-3528-4041-60 (Fax) 49-3528-4041-65	**Yes**	B

Ordering Information:

Vendor	Catalog Number	Description	Size/Units	Bulk Quantities	Certificate of Analysis Available
Sigma-Aldrich	**36,127-5**	97% Non-radioactive FLT standard	25 mg	N/A	Yes
ABX	**122**	> 95% Non-radioactive FLT standard	10 mg, 20 mg, 50 mg, 100 mg	N/A	Yes

NCI Internal Specifications: For all non-USP reagents, the certificate of analysis will be compared with the listed internal specifications to ensure that the manufacturers are still testing the product consistently and utilizing the same standards to determine quality, purity, and identity of the reagents. For 3'-Deoxy-3'-[^{19}F]Fluorothymidine additional tests to assure purity and identity will be done by NCI or the manufacturing sites as specified below:

Parameter	Test Methodology	Specification
Identity	FT-NMR	Conforms to Standard Structure
Melting Point	Melting Point Determination	167-180°C
Purity	--	> 95%

Required NCI / Site Tests for Release:

Parameter	Test Methodology	Specification
Identity and Purity	HPLC-MS (HPLC method of GEN-Q119)	>95% of UV 254 nm absorbance post void volume is associated with FLT peak. Mass spectrometry (ES^- M/Z 289) provides verification that peak is FLT.

Regulatory Affairs Approval: _____ **Date:** _____

Signature

Cancer Imaging Program, *Confidential--Use and restriction of this document is set forth in Transfer Agreement executed with the National Cancer Institute (NCI).*